It depends what you consider the market.
Kaken basically had 200,000 new patients in the first year, I think BOT will have more.
Not only that. Every BOT patient that renews the script , effectively doubles the patient numbers, since most Japanese on average buy 1 script only. Most americans buy 2.
So although market penetration might oly be 2% or whatever.... if they renew 4 scripts on average.... that is the exquivalent of 4x market penetration in income.
Based on what happened in Japan, it is entirely feasable that the sales in year 1 will be around the 1 billion mark.
Take the same year 1 sales Kaken had, adjust for USA being 3 x the size, and adjust for the fact that USA on average renew 2 scripts where as Japan do not renew. That gives you 900,000 USD in sales ~ or about 1.3 to 1.4 Billion in AUS sales.
The first quarter report will be the first indication of where on that scale we are.
- Forums
- ASX - By Stock
- BOT
- Ann: Trading Halt
Ann: Trading Halt, page-280
-
- There are more pages in this discussion • 60 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BOT (ASX) to my watchlist
|
|||||
Last
34.5¢ |
Change
0.020(6.15%) |
Mkt cap ! $624.4M |
Open | High | Low | Value | Volume |
32.5¢ | 34.5¢ | 32.5¢ | $2.676M | 7.955M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 19000 | 34.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
34.5¢ | 48210 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 19000 | 0.340 |
7 | 82532 | 0.335 |
7 | 230432 | 0.330 |
16 | 300342 | 0.325 |
12 | 365290 | 0.320 |
Price($) | Vol. | No. |
---|---|---|
0.345 | 48210 | 1 |
0.350 | 619317 | 10 |
0.355 | 106203 | 4 |
0.360 | 348925 | 7 |
0.365 | 100000 | 1 |
Last trade - 16.10pm 03/07/2024 (20 minute delay) ? |
Featured News
BOT (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, CEO & MD
Anthony Noble
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online